Epidermal growth factor receptor in glioma: Signal transduction, neuropathology, imaging, and radioresistance1

Neoplasia

Volumn 12, Issue 9, 2010, Pages 675-684

  Hatanpaa, Kimmo J ^a   Burma, Sandeep ^a,b   Zhao, Dawen ^a,b   Habib, Amyn A ^a,b,c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; CARBON 11; CEDIRANIB; CETUXIMAB; DOUBLE STRANDED DNA; DUAL SPECIFICITY PHOSPHATASE 6; EPHRIN A2; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPITHELIAL MEMBRANE PROTEIN 1; ERLOTINIB; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; INTERLEUKIN 8; LUTETIUM 177; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TECHNETIUM 99M; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG;

CANCER SURVIVAL; CARCINOGENESIS; CARCINOGENICITY; DNA REPAIR; DNA STRAND BREAKAGE; DRUG TARGETING; EXON; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LIGAND BINDING; NEUROIMAGING; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN; RADIOSENSITIVITY; REVIEW; SIGNAL TRANSDUCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT OUTCOME; TUMOR VASCULARIZATION; WILD TYPE;

EID: 77956868654     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.10688     Document Type: Review

References (151)

1. Carpenter G and Cohen S (1990). Epidermal growth factor. J Biol Chem 265, 7709-7712.
2. Gullick WJ (1991). Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull 47, 87-98.
3. Huang PH, Xu AM, and White FM (2009). Oncogenic EGFR signaling networks in glioma. Sci Signal 2, re6.
4. Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF, and Collins VP (1991). Genes for epidermal growth factor receptor, transforming growth factor α, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 51, 2164-2172.
5. Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS, and Vogelstein B (1992). Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 89, 2965-2969.
6. Biernat W, Huang H, Yokoo H, Kleihues P, and Ohgaki H (2004). Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas. Brain Pathol 14, 131-136.
7. Aaronson SA (1991). Growth factors and cancer. Science 254, 1146-1153.
8. Tang P, Steck PA, and Yung WK (1997). The autocrine loop of TGF-α/EGFR and brain tumors. J Neurooncol 35, 303-314.
9. Mishima K, Higashiyama S, Asai A, Yamaoka K, Nagashima Y, Taniguchi N, Kitanaka C, Kirino T, and Kuchino Y (1998). Heparin-binding epidermal growth factor-like growth factor stimulates mitogenic signaling and is highly expressed in human malignant gliomas. Acta Neuropathol (Berl) 96, 322-328.
10. Nicholas MK, Lukas RV, Jafri NF, Faoro L, and Salgia R (2006). Epidermal growth factor receptor-mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res 12, 7261-7270.
11. Batra SK, Castelino-Prabhu S, Wikstrand CJ, Zhu X, Humphrey PA, Friedman HS, and Bigner DD (1995). Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ 6, 1251-1259.
12. Moscatello DK, Montgomery RB, Sundareshan P, McDanel H, Wong MY, and Wong AJ (1996). Transformational and altered signal transduction by a naturally occurring mutant EGF receptor. Oncogene 13, 85-96.
13. Nagane M, Coufal F, Lin H, Bogler O, Cavenee WK, and Huang HJ (1996). A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 56, 5079-5086.
14. Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK, and Huang HJ (1994). A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA 91, 7727-7731.
15. Holland EC, Hively WP, DePinho RA, and Varmus HE (1998). A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev 12, 3675-3685.
16. Lal A, Glazer CA, Martinson HM, Friedman HS, Archer GE, Sampson JH, and Riggins GJ (2002). Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res 62, 3335-3339.
17. Boockvar JA, Kapitonov D, Kapoor G, Schouten J, Counelis GJ, Bogler O, Snyder EY, McIntosh TK, and O'Rourke DM (2003). Constitutive EGFR signaling confers a motile phenotype to neural stem cells. Mol Cell Neurosci 24, 1116-1130.
18. Ramnarain DB, Park S, Lee DY, Hatanpaa KJ, Scoggin SO, Otu H, Libermann TA, Raisanen JM, Ashfaq R, Wong ET, et al. (2006).Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells. Cancer Res 66, 867-874.
19. Mukherjee B, McEllin B, Camacho CV, Tomimatsu N, Sirasanagandala S, Nannepaga S, Hatanpaa KJ, Mickey B, Madden C, Maher E, et al. (2009). EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. Cancer Res 69, 4252-4259.
20. Heimberger AB, Crotty LE, Archer GE, Hess KR, Wikstrand CJ, Friedman AH, Friedman HS, Bigner DD, and Sampson JH (2003). Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res 9, 4247-4254.
21. Mendelsohn J and Baselga J (2000). The EGF receptor family as targets for cancer therapy. Oncogene 19, 6550-6565.
22. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500.
23. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350, 2129-2139.
24. Dowell JE and Minna JD (2006). EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer. Nat Clin Pract Oncol 3,170-171.
25. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, et al. (2009). Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361, 958-967.
26. Karpel-Massler G, Schmidt U, Unterberg A, and Halatsch ME (2009). Therapeutic inhibition of the epidermal growth factor receptor in high-grade gliomas: where do we stand? Mol Cancer Res 7, 1000-1012.
27. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, et al. (2005).Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353, 2012-2024.
28. Friedman HS and Bigner DD (2005). Glioblastoma multiforme and the epidermal growth factor receptor. N Engl J Med 353, 1997-1999.
29. Brown PD, Krishnan S, Sarkaria JN, Wu W, Jaeckle KA, Uhm JH, Geoffroy FJ, Arusell R, Kitange G, Jenkins RB, et al. (2008). Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol 26, 5603-5609.
30. Burger PC, Pearl DK, Aldape K, Yates AJ, Scheithauer BW, Passe SM, Jenkins RB, and James CD (2001). Small cell architecture-a histological equivalent of EGFR amplification in glioblastoma multiforme? J Neuropathol Exp Neurol 60, 1099-1104.
31. Ohgaki H and Kleihues P (2007). Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170, 1445-1453.
32. Tohma Y, Gratas C, Biernat W, Peraud A, Fukuda M, Yonekawa Y, Kleihues P, and Ohgaki H (1998). PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J Neuropathol Exp Neurol 57, 684-689.
33. Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, and Ohgaki H (1996). Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6, 217-223;discussion 223-214.
34. Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, Sawaya R, and Aldape K (2005). Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 11, 1462-1466.
35. Aldape KD, Ballman K, Furth A, Buckner JC, Giannini C, Burger PC, Scheithauer BW, Jenkins RB, and James CD (2004). Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol 63, 700-707.
36. Suri V, Das P, Jain A, Sharma MC, Borkar SA, Suri A, Gupta D, and Sarkar C (2009). Pediatric glioblastomas: a histopathological and molecular genetic study. Neuro Oncol 11, 274-280.
37. Sung T, Miller DC, Hayes RL, Alonso M, Yee H, and Newcomb EW (2000). Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas. Brain Pathol 10, 249-259.
38. Korshunov A, Golanov A, and Sycheva R (2002). Immunohistochemical markers for prognosis of cerebral glioblastomas. J Neurooncol 58, 217-236.
39. He J, Mokhtari K, Sanson M, Marie Y, Kujas M, Huguet S, Leuraud P, Capelle L, Delattre JY, Poirier J, et al. (2001). Glioblastomas with an oligodendroglial component: a pathological and molecular study. J Neuropathol Exp Neurol 60, 863-871.
40. Meis JM, Martz KL, and Nelson JS (1991). Mixed glioblastoma multiforme and sarcoma. A clinicopathologic study of 26 radiation therapy oncology group cases. Cancer 67, 2342-2349.
41. Kozak KR and Moody JS (2009). Giant cell glioblastoma: a glioblastoma subtype with distinct epidemiology and superior prognosis. Neuro Oncol 11, 833-841.
42. Miller CR, Dunham CP, Scheithauer BW, and Perry A (2006). Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas. J Clin Oncol 24, 5419-5426.
43. Louis DN, Ohgaki H, Wiestler OD, and Cavenee WK (Eds.) (2007). In WHO Classification of Tumours of the Central Nervous System. Lyon, France.
44. Perry A, Aldape KD, George DH, and Burger PC (2004). Small cell astrocytoma: an aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma. Cancer 101, 2318-2326.
45. Reis RM, Konu-Lebleblicioglu D, Lopes JM, Kleihues P, and Ohgaki H (2000). Genetic profile of gliosarcomas. Am J Pathol 156, 425-432.
46. Peraud A, Watanabe K, Schwechheimer K, Yonekawa Y, Kleihues P, and Ohgaki H (1999). Genetic profile of the giant cell glioblastoma. Lab Invest 79, 123-129.
47. Kleinschmidt-DeMasters BK, Lillehei KO, and Varella-Garcia M (2005). Glioblastomas in the older old. Arch Pathol Lab Med 129, 624-631.
48. Okada Y, Hurwitz EE, Esposito JM, Brower MA, Nutt CL, and Louis DN (2003). Selection pressures of TP53 mutation and microenvironmental location influence epidermal growth factor receptor gene amplification in human glioblastomas. Cancer Res 63, 413-416.
49. Simmons ML, Lamborn KR, Takahashi M, Chen P, Israel MA, Berger MS, Godfrey T, Nigro J, Prados M, Chang S, et al. (2001). Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res 61, 1122-1128.
50. Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, O'Fallon JR, Schaefer PL, Scheithauer BW, James CD, et al. (2001). PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93, 1246-1256.
51. Shinojima N, Tada K, Shiraishi S, Kamiryo T, Kochi M, Nakamura H, Makino K, Saya H, Hirano H, Kuratsu J, et al. (2003). Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 63, 6962-6970.
52. Batchelor TT, Betensky RA, Esposito JM, Pham LD, Dorfman MV, Piscatelli N, Jhung S, Rhee D, and Louis DN (2004). Age-dependent prognostic effects of genetic alterations in glioblastoma. Clin Cancer Res 10, 228-233.
53. Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M, Sabel M, Steinbach JP, Heese O, Reifenberger G, et al. (2007). Long-term survival with glioblastoma multiforme. Brain 130, 2596-2606.
54. Mishani E, Abourbeh G, Eiblmaier M, and Anderson CJ (2008). Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities. Curr Pharm Des 14, 2983-2998.
55. Pantaleo MA, Nannini M, Maleddu A, Fanti S, Nanni C, Boschi S, Lodi F, Nicoletti G, Landuzzi L, Lollini PL, et al. (2009). Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer. Ann Oncol 20, 213-226.
56. Cai W, Niu G, and Chen X (2008). Multimodality imaging of the HER-kinase axis in cancer. Eur J Nucl Med Mol Imaging 35, 186-208.
57. Velikyan I, Sundberg AL, Lindhe O, Hoglund AU, Eriksson O, Werner E, Carlsson J, Bergstrom M, Langstrom B, and Tolmachev V (2005). Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors. J Nucl Med 46, 1881-1888.
58. Cai W, Chen K, He L, Cao Q, Koong A, and Chen X (2007). Quantitative PETof EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging 34, 850-858.
59. Tolmachev V, Friedman M, Sandstrom M, Eriksson TL, Rosik D, Hodik M, Stahl S, Frejd FY, and Orlova A (2009). Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry. J Nucl Med 50, 274-283.
60. Takahashi H, Herlyn D, Atkinson B, Powe J, Rodeck U, Alavi A, Bruce DA, and Koprowski H (1987). Radioimmunodetection of human glioma xenografts by monoclonal antibody to epidermal growth factor receptor. Cancer Res 47, 3847-3850.
61. Pal A, Glekas A, Doubrovin M, Balatoni J, Namavari M, Beresten T, Maxwell D, Soghomonyan S, Shavrin A, Ageyeva L, et al. (2006).Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography. Mol Imaging Biol 8, 262-277.
62. Takasu S, Takahashi T, Okamoto S, Oriuchi N, Nakayashiki N, Okamoto K, Muramatsu H, Hayashi T, Nakahara N, Mizuno M, et al. (2003). Radioimmunoscintigraphy of intracranial glioma xenograft with a technetium-99m-labeled mouse monoclonal antibody specifically recognizing type III mutant epidermal growth factor receptor. J Neurooncol 63, 247-256.
63. Liu N, Li M, Li X, Meng X, Yang G, Zhao S, Yang Y, Ma L, Fu Z, and Yu J (2009). PET-based biodistribution and radiation dosimetry of epidermal growth factor receptor-selective tracer 11C-PD153035 in humans. J Nucl Med 50, 303-308.
64. Shu X, Royant A, Lin MZ, Aguilera TA, Lev-Ram V, Steinbach PA, and Tsien RY (2009). Mammalian expression of infrared fluorescent proteins engineered from a bacterial phytochrome. Science 324, 804-807.
65. Ke S, Wen X, Gurfinkel M, Charnsangavej C, Wallace S, Sevick-Muraca EM, and Li C (2003). Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts. Cancer Res 63, 7870-7875.
66. Hama Y, Urano Y, Koyama Y, Choyke PL, and Kobayashi H (2007). Activatable fluorescent molecular imaging of peritoneal metastases following pretargeting with a biotinylated monoclonal antibody. Cancer Res 67, 3809-3817.
67. Yang L, Mao H, Wang YA, Cao Z, Peng X, Wang X, Duan H, Ni C, Yuan Q, Adams G, et al. (2009). Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging. Small 5, 235-243.
68. Adams KE, Ke S, Kwon S, Liang F, Fan Z, Lu Y, Hirschi K, Mawad ME, Barry MA, and Sevick-Muraca EM (2007). Comparison of visible and near-infrared wavelength-excitable fluorescent dyes for molecular imaging of cancer. J Biomed Opt 12, 024017.
69. Barker FG II and Chang SM (2006). Improving resection of malignant glioma. Lancet Oncol 7, 359-360.
70. Jaffer FA and Weissleder R (2005). Molecular imaging in the clinical arena. JAMA 293, 855-862.
71. Suwa T, Ozawa S, Ueda M, Ando N, and Kitajima M (1998).Magnetic resonance imaging of esophageal squamous cell carcinoma using magnetite particles coated with anti-epidermal growth factor receptor antibody. Int J Cancer 75, 626-634.
72. Aghi M, Gaviani P, Henson JW, Batchelor TT, Louis DN, and Barker FG II (2005). Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma. Clin Cancer Res 11, 8600-8605.
73. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, et al. (2007). AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11, 83-95.
74. Cerniglia GJ, Pore N, Tsai JH, Schultz S, Mick R, Choe R, Xing X, Durduran T, Yodh AG, Evans SM, et al. (2009). Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy. PLoS One 4, e6539.
75. Huang HS, Nagane M, Klingbeil CK, Lin H, Nishikawa R, Ji XD, Huang CM, Gill GN, Wiley HS, and Cavenee WK (1997). The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 272, 2927-2935.
76. Schmidt MH, Furnari FB, Cavenee WK, and Bogler O (2003). Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization. Proc Natl Acad Sci USA 100, 6505-6510.
77. Wiley HS (2003). Trafficking of the ErbB receptors and its influence on signaling. Exp Cell Res 284, 78-88.
78. Di Fiore PP and Gill GN (1999). Endocytosis and mitogenic signaling. Curr Opin Cell Biol 11, 483-488.
79. Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, Palotie A, Inge L, Smith BL, Sawyers CL, and Mischel PS (2003). Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 63, 2742-2746.
80. Moscatello DK, Holgado-Madruga M, Emlet DR, Montgomery RB, and Wong AJ (1998). Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J Biol Chem 273, 200-206.
81. Narita Y, Nagane M, Mishima K, Huang HJ, Furnari FB, and Cavenee WK (2002). Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas. Cancer Res 62, 6764-6769.
82. Prigent SA, Nagane M, Lin H, Huvar I, Boss GR, Feramisco JR, Cavenee WK, and Huang HS (1996). Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway. J Biol Chem 271, 25639-25645.
83. Lorimer IA and Lavictoire SJ (2001). Activation of extracellular-regulated kinases by normal and mutant EGF receptors. Biochim Biophys Acta 1538, 1-9.
84. Zhan Y and O'Rourke DM (2004). SHP-2-dependent mitogen-activated protein kinase activation regulates EGFRvIII but not wild-type epidermal growth factor receptor phosphorylation and glioblastoma cell survival. Cancer Res 64, 8292-8298.
85. Nagane M, Levitzki A, Gazit A, Cavenee WK, and Huang HJ (1998). Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc Natl Acad Sci USA 95, 5724-5729.
86. Antonyak MA, Kenyon LC, Godwin AK, James DC, Emlet DR, Okamoto I, Tnani M, Holgado-Madruga M, Moscatello DK, and Wong AJ (2002). Elevated JNK activation contributes to the pathogenesis of human brain tumors. Oncogene 21, 5038-5046.
87. Micallef J, Taccone M, Mukherjee J, Croul S, Busby J, Moran MF, and Guha A (2009). Epidermal growth factor receptor variant III-induced glioma invasion is mediated through myristoylated alanine-rich protein kinase C substrate overexpression. Cancer Res 69, 7548-7556.
88. Waterman H and Yarden Y (2001).Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases. FEBS Lett 490, 142-152.
89. Wiley HS (1988). Anomalous binding of epidermal growth factor to A431 cells is due to the effect of high receptor densities and a saturable endocytic system. J Cell Biol 107, 801-810.
90. Lund KA, Opresko LK, Starbuck C, Walsh BJ, and Wiley HS (1990). Quantitative analysis of the endocytic system involved in hormone-induced receptor internalization. J Biol Chem 265, 15713-15723.
91. Luwor RB, Zhu HJ, Walker F, Vitali AA, Perera RM, Burgess AW, Scott AM, and Johns TG (2004). The tumor-specific de2-7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR. Oncogene 23, 6095-6104.
92. Sporn MB and Todaro GJ (1980). Autocrine secretion and malignant transformation of cells. N Engl J Med 303, 878-880.
93. Di Marco E, Pierce JH, Fleming TP, Kraus MH, Molloy CJ, Aaronson SA, and Di Fiore PP (1989). Autocrine interaction between TGF α and the EGFreceptor: quantitative requirements for induction of the malignant phenotype. Oncogene 4, 831-838.
94. Filmus J, Shi W, and Spencer T (1993). Role of transforming growth factor α (TGF-α) in the transformation of ras-transfected rat intestinal epithelial cells. Oncogene 8, 1017-1022.
95. Hatano M, Eguchi J, Tatsumi T, Kuwashima N, Dusak JE, Kinch MS, Pollack IF, Hamilton RL, Storkus WJ, and Okada H (2005). EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. Neoplasia 7, 717-722.
96. Wykosky J, Gibo DM, Stanton C, and Debinski W (2005). EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol Cancer Res 3, 541-551.
97. Miao H, Li DQ, Mukherjee A, Guo H, Petty A, Cutter J, Basilion JP, Sedor J, Wu J, Danielpour D, et al. (2009). EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. Cancer Cell 16, 9-20.
98. Liu F, Park PJ, Lai W, Maher E, Chakravarti A, Durso L, Jiang X, Yu Y, Brosius A, Thomas M, et al. (2006). A genome-wide screen reveals functional gene clusters in the cancer genome and identifies EphA2 as a mitogen in glioblastoma. Cancer Res 66, 10815-10823.
99. Wykosky J, Gibo DM, Stanton C, and Debinski W (2008). Interleukin-13 receptor α 2, EphA2, and Fos-related antigen 1 as molecular denominators of high-grade astrocytomas and specific targets for combinatorial therapy. Clin Cancer Res 14, 199-208.
100. Debinski Wand Gibo DM (2005). Fos-related antigen 1 modulates malignant features of glioma cells. Mol Cancer Res 3, 237-249.
101. Tatenhorst L, Senner V, Puttmann S, and Paulus W (2004). Regulators of Gprotein signaling 3 and 4 (RGS3, RGS4) are associated with glioma cell motility. J Neuropathol Exp Neurol 63, 210-222.
102. Brat DJ, Bellail AC, and Van Meir EG (2005). The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro-oncol 7, 122-133.
103. Bredel M, Bredel C, Juric D, Harsh GR, Vogel H, Recht LD, and Sikic BI (2005). Functional network analysis reveals extended gliomagenesis pathway maps and three novelMYC-interacting genes in human gliomas. Cancer Res 65, 8679-8689.
104. Sparmann A and Bar-Sagi D (2004). Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 6, 447-458.
105. Wen XF, Yang G, Mao W, Thornton A, Liu J, Bast RC, and Le XF (2006). HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene 25, 6986-6996.
106. de la Iglesia N, Konopka G, Lim KL, Nutt CL, Bromberg JF, Frank DA, Mischel PS, Louis DN, and Bonni A (2008). Deregulation of a STAT3-interleukin 8 signaling pathway promotes human glioblastoma cell proliferation and invasiveness. J Neurosci 28, 5870-5878.
107. Zelinski DP, Zantek ND, Stewart JC, Irizarry AR, and Kinch MS (2001). EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 61, 2301-2306.
108. Duxbury MS, Ito H, Zinner MJ, Ashley SW, and Whang EE (2004). EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma. Oncogene 23, 1448-1456.
109. Wright JH, Wang X, Manning G, LaMere BJ, Le P, Zhu S, Khatry D, Flanagan PM, Buckley SD, Whyte DB, et al. (2003). The STE20 kinase HGK is broadly expressed in human tumor cells and can modulate cellular transformation, invasion, and adhesion. Mol Cell Biol 23, 2068-2082.
110. Collins CS, Hong J, Sapinoso L, Zhou Y, Liu Z, Micklash K, Schultz PG, and Hampton GM (2006). A small interfering RNA screen for modulators of tumor cell motility identifies MAP4K4 as a promigratory kinase. Proc Natl Acad Sci USA 103, 3775-3780.
111. Warmka JK, Mauro LJ, and Wattenberg EV (2004). Mitogen-activated protein kinase phosphatase-3 is a tumor promoter target in initiated cells that express oncogenic Ras. J Biol Chem 279, 33085-33092.
112. Bloethner S, Chen B, Hemminki K, Muller-Berghaus J, Ugurel S, Schadendorf D, and Kumar R (2005). Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines. Carcinogenesis 26, 1224-1232.
113. Sato M, Vaughan MB, Girard L, Peyton M, Lee W, Shames DS, Ramirez RD, Sunaga N, Gazdar AF, Shay JW, et al. (2006).Multiple oncogenic changes (K-RAS (V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res 66, 2116-2128.
114. Arslan AA, Gold LI, Mittal K, Suen TC, Belitskaya-Levy I, Tang MS, and Toniolo P (2005). Gene expression studies provide clues to the pathogenesis of uterine leiomyoma: new evidence and a systematic review. Hum Reprod 20, 852-863.
115. Halatsch ME, Low S, Mursch K, Hielscher T, Schmidt U, Unterberg A, Vougioukas VI, and Feuerhake F (2009). Candidate genes for sensitivity and resistance of human glioblastoma multiforme cell lines to erlotinib. Laboratory investigation. J Neurosurg 111, 211-218.
116. Giancotti V (2006). Breast cancer markers. Cancer Lett 243, 145-159.
117. Nyati MK, Morgan MA, Feng FY, and Lawrence TS (2006). Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer 6, 876-885.
118. Balaban N, Moni J, Shannon M, Dang L, Murphy E, and Goldkorn T (1996).The effect of ionizing radiation on signal transduction: antibodies to EGF receptor sensitize A431 cells to radiation. Biochim Biophys Acta 1314, 147-156.
119. Das AK, Chen BP, Story MD, Sato M, Minna JD, Chen DJ, and Nirodi CS (2007). Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lung carcinoma. Cancer Res 67, 5267-5274.
120. Das AK, Sato M, Story MD, Peyton M, Graves R, Redpath S, Girard L, Gazdar AF, Shay JW, Minna JD, et al. (2006). Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation. Cancer Res 66, 9601-9608.
121. Akimoto T, Hunter NR, Buchmiller L, Mason K, Ang KK, and Milas L (1999). Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 5, 2884-2890.
122. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, Fu KK, and Milas L (2002). Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62, 7350-7356.
123. Milas L, Fan Z, Andratschke NH, and Ang KK (2004). Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies. Int J Radiat Oncol Biol Phys 58, 966-971.
124. Sheridan MT, O'Dwyer T, Seymour CB, and Mothersill CE (1997). Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck. Radiat Oncol Investig 5, 180-186.
125. Contessa JN, Hampton J, Lammering G, Mikkelsen RB, Dent P, Valerie K, and Schmidt-Ullrich RK (2002). Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells. Oncogene 21, 4032-4041.
126. Dent P, Reardon DB, Park JS, Bowers G, Logsdon C, Valerie K, and Schmidt-Ullrich R (1999). Radiation-induced release of transforming growth factor α activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell 10, 2493-2506.
127. Schmidt-Ullrich RK, Mikkelsen RB, Dent P, Todd DG, Valerie K, Kavanagh BD, Contessa JN, Rorrer WK, and Chen PB (1997). Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 15, 1191-1197.
128. Schmidt-Ullrich RK, Valerie K, Fogleman PB, and Walters J (1996). Radiationinduced autophosphorylation of epidermal growth factor receptor in human malignant mammary and squamous epithelial cells. Radiat Res 145, 81-85.
129. Dittmann K, Mayer C, Fehrenbacher B, Schaller M, Raju U, Milas L, Chen DJ, Kehlbach R, and Rodemann HP (2005). Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem 280, 31182-31189.
130. Burma S and Chen DJ (2004). Role of DNA-PK in the cellular response to DNA double-strand breaks. DNA Repair (Amst) 3, 909-918.
131. Burma S, Chen BP, and Chen DJ (2006). Role of non-homologous end joining (NHEJ) in maintaining genomic integrity. DNA Repair (Amst) 5, 1042-1048.
132. Dittmann K, Mayer C, and Rodemann HP (2005). Inhibition of radiationinducedEGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity. Radiother Oncol 76, 157-161.
133. Bandyopadhyay D, Mandal M, Adam L, Mendelsohn J, and Kumar R (1998). Physical interaction between epidermal growth factor receptor and DNAdependent protein kinase in mammalian cells. J Biol Chem 273, 1568-1573.
134. Golding SE, Morgan RN, Adams BR, Hawkins AJ, Povirk LF, and Valerie K (2009). Pro-survival AKTand ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells. Cancer Biol Ther 8, 730-738.
135. Kao GD, Jiang Z, Fernandes AM, Gupta AK, and Maity A (2007). Inhibition of phosphatidylinositol-3-OH kinase/Akt signaling impairs DNA repair in glioblastoma cells following ionizing radiation. J Biol Chem 282, 21206-21212.
136. Rodemann HP, Dittmann K, and ToulanyM (2007). Radiation-induced EGFRsignaling and control of DNA-damage repair. Int J Radiat Biol 83, 781-791.
137. Toulany M, Kehlbach R, Florczak U, Sak A, Wang S, Chen J, Lobrich M, and Rodemann HP (2008). Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair. Mol Cancer Ther 7, 1772-1781.
138. McLendon RE, Turner K, Perkinson K, and Rich J (2007). Second messenger systems in human gliomas. Arch Pathol Lab Med 131, 1585-1590.
139. Lammering G, Hewit TH, Valerie K, Contessa JN, Amorino GP, Dent P, and Schmidt-Ullrich RK (2003). EGFRvIII-mediated radioresistance through a strong cytoprotective response. Oncogene 22, 5545-5553.
140. Chu CT, Everiss KD, Wikstrand CJ, Batra SK, Kung HJ, and BignerDD (1997). Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). Biochem J 324(pt 3), 855-861.
141. Learn CA, Hartzell TL, Wikstrand CJ, Archer GE, Rich JN, Friedman AH, Friedman HS, Bigner DD, and Sampson JH (2004). Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clin Cancer Res 10, 3216-3224.
142. Li B, Yuan M, Kim IA, Chang CM, Bernhard EJ, and Shu HK (2004). Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin. Oncogene 23, 4594-4602.
143. Friedmann BJ, Caplin M, Savic B, Shah T, Lord CJ, Ashworth A, Hartley JA, and Hochhauser D (2006). Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment. Mol Cancer Ther 5, 209-218.
144. Altomare DA and Testa JR (2005). Perturbations of the AKT signaling pathway in human cancer. Oncogene 24, 7455-7464.
145. Edwards E, Geng L, Tan J, Onishko H, Donnelly E, and Hallahan DE (2002). Phosphatidylinositol 3-kinase/Akt signaling in the response of vascular endothelium to ionizing radiation. Cancer Res 62, 4671-4677.
146. Friedmann B, Caplin M, Hartley JA, and Hochhauser D (2004). Modulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib (ZD1839). Clin Cancer Res 10, 6476-6486.
147. Bozulic L, Surucu B, Hynx D, and Hemmings BA (2008). PKBα/Akt1 acts downstreamofDNA-PK in theDNA double-strand break response and promotes survival. Mol Cell 30, 203-213.
148. Lees-Miller SP (2008). PIKK-ing a new partner: a new role for PKB in the DNA damage response. Cancer Cell 13, 379-380.
149. Boehme KA, Kulikov R, and Blattner C (2008). p53 stabilization in response to DNA damage requires Akt/PKB and DNA-PK. Proc Natl Acad Sci USA 105, 7785-7790.
150. Habib AA, Chun SJ, Neel BG, and Vartanian T (2003). Increased expression of epidermal growth factor receptor induces sequestration of extracellular signal-related kinases and selective attenuation of specific epidermal growth factor-mediated signal transduction pathways. Mol Cancer Res 1, 219-233.
151. Sarkisian CJ, Keister BA, Stairs DB, Boxer RB, Moody SE, and Chodosh LA (2007). Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol 9, 493-505.